Application No.: 10/694,383 Reply to Final Office Action mailed on August 18, 2009 Page 2 of 12

Amendments to the Claims:

This claim listing will replace all prior versions and listings of claims in the application: Claim Listing:

- 1-11, (Cancelled)
- (Previously presented) An immunostimulatory oligonucleotide compound comprising a sequence of formula (III):

wherein:

Y is a non-natural pyrimidine nucleoside;

Z is guanosine, 2'-deoxy-guanosine or a non-natural purine nucleoside;

each X independently is a naturally occurring nucleoside or an immunostimulatory moiety:

wherein Um-U1 represents an upstream potentiation domain, where each U independently is a naturally occurring nucleoside or an immunostimulatory moiety;

wherein D1-Dm represents a downstream potentiation domain , where each D independently is a naturally occurring nucleoside or an immunostimulatory moiety; and

m, at each occurrence, represents a number from 0 to 30; and

wherein the immunostimulatory moiety is selected from the group consisting of C3-alkyl linker, 2-aminobutyl-1,3-propanediol linker, β -L-deoxynucleoside, 1',2'-dideoxyribose, C3-linker, Spacer 18, 3'-deoxynucleoside, 2'-O-propargyl-ribonucleoside, Spacer 9 and 2'-5' linkage; and

wherein at least one X, U, or D is an immunostimulatory moiety.

- 13. (Canceled)
- (Previously presented) An immunostimulatory oligonucleotide compound comprising a sequence of formula (III):

Application No.: 10/694,383

Reply to Final Office Action mailed on August 18, 2009

Page 3 of 12

wherein:

Y is a non-natural pyrimidine nucleoside;

Z is guanosine, 2'-deoxy-guanosine or a non-natural purine nucleoside;

X1 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of C3-alkyl linker, 2-aminobutyl-1,3-propanediol linker, and β -L-deoxynucleoside;

X2 is a naturally occurring nucleoside or an immunostimulatory moiety that is a 2-aminobutyl-1,3-propanediol linker;

X3 is a naturally occurring nucleoside or an immunostimulatory moiety that is a nucleoside methylphosphonate;

X4 is a naturally occurring nucleoside or a nucleoside methylphosphonate;

U1 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of 1'.2'-dideoxyribose, C3-linker, and 2'-O-methyl-ribonucleoside;

U2 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of 1',2'-dideoxyribose, C3-linker, Spacer 18, 3'-deoxynucleoside, nucleoside methylphosphonate, β -L-deoxynucleoside, and 2'-O-propargylribonucleoside;

U3 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of 1',2'-dideoxyribose, C3-linker, Spacer 9, Spacer 18, nucleoside methylphosphonate, and 2'-5' linkage;

each U_{m} is independently a naturally occurring nucleoside or an immunostimulatory moiety;

D1 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of 1',2'-dideoxyribose and nucleoside methylphosphonate;

Application No.: 10/694,383

Reply to Final Office Action mailed on August 18, 2009

Page 4 of 12

D2 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of 1',2'-dideoxyribose, C3-linker, Spacer 9, Spacer 18, 2-aminobutyl-1,3-propanediol linker, nucleoside methylphosphonate, and β-L-deoxynucleoside;

D3 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of 3'-deoxynucleoside, 2'-O-propargylribonucleoside; and 2'-5' linkage; and

each D_m is independently a naturally occurring nucleoside or an immunostimulatory moiety;

provided that at least one of X1, X2, X3, X4, U1, U2, U3, D1, D2 or D3 is an immunostimulatory moiety.

- (Withdrawn) The immunostimulatory oligonucleotide compound of claim 12, wherein
 U2 and U3 are both the same immunostimulatory moiety selected from the group
 consisting of 1',2'-didoxyribose, C3-linker, or β-L-deoxynucleoside.
- 16. (Withdrawn) The immunostimulatory oligonucleotide compound of claim 12, wherein U3 and U4 are both the same immunostimulatory moiety selected from the group consisting of nucleoside methylphosphonate and 2'-O-methoxyethylribonucleoside.
- (Withdrawn) The immunostimulatory oligonucleotide compound of claim 12, wherein U5 and U6 are both the same immunostimulatory moiety selected from the group consisting of 1',2'-dideoxyribose and C3-linker.
- (Withdrawn) The immunostimulatory oligonucleotide compound of claim 12, wherein X1 and U3 are both 1',2'-dideoxyribose.
- (Withdrawn) The immunostimulatory oligonucleotide compound of claim 12, wherein D2 and D3 are both the same immunostimulatory moiety selected from the group

Application No.: 10/694,383

Reply to Final Office Action mailed on August 18, 2009

Page 5 of 12

consisting of 1',2'-dideoxyribose and β-L-deoxynucleoside.

20-38. (Cancelled)

39. (Previously presented) The immunostimulatory oligonucleotide compound of claim 12,

 $wherein\ Y\ is\ selected\ from\ 5-hydroxycytosine,\ 5-hydroxymethycytosine,\ N4-alkylcytosine\ and$

4-thiouracil.

40. (Previously presented) The immunostimulatory oligonucleotide compound of claim 14,

 $wherein\ Y\ is\ selected\ from\ 5-hydroxycytosine,\ 5-hydroxymethycytosine,\ N4-alkylcytosine\ and$

4-thiouracil.